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Abstract
Background: Primary amyloidosis of the breast is an unusual benign disease that mostly occurs in postmenopausal
elderly women. Amyloidosis is the deposition of amorphous protein within tissues. Breast biopsy is necessary to
make a definite diagnosis in order to avoid unnecessary surgical methods. Localized primary amyloidosis of the
breast has a good prognosis. However, secondary amyloidosis is a systemic disease and has a poor prognosis.
Case presentation: We report the case of a 77-year-old female with primary amyloidosis of the breast. She noticed
a lump in her left breast. Mammographic and ultrasonographic examinations indicated breast cancer. However,
core needle biopsy showed amyloidosis, not cancer of the breast. For further examinations, the patient visited the
outpatient clinics of the hematology, dermatology, and gastroenterology departments. She underwent bone
marrow aspiration, computed tomography, cardiac ultrasonography, random skin biopsy, gastrofiberscopy, and
colonofiberscopy. Plasma cell myeloma and systemic amyloidosis were ruled out, and localized breast amyloidosis
was highly suspected. Lumpectomy was performed to make a definite diagnosis, and histological evaluations
revealed that this patient had localized amyloidosis of the breast, and the deposited amyloid protein was of the
amyloid light chain kappa type.
Conclusions: Breast biopsy is necessary in order to avoid unnecessary surgical technique. A diagnosis should be
achieved only through a histological evaluation. The main treatment of localized primary amyloidosis of the breast
is surgical removal.
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Background
Amyloidosis of the breast is a very rare disease. We
experienced a case of primary amyloidosis of the
breast for the first time in 27 years at our institution.
Amyloidosis of the breast was first reported in 1973
[1], and most of the reported cases involved postmen-
opausal elderly women. Breast amyloidosis can be a
part of a systemic disease or may be localized to the
breast. Furthermore, amyloidosis of the breast is re-
ported to be often associated with an underlying
breast cancer [2].
Primary amyloidosis of the breast typically presents
with a painless and palpable mass [3]. The common
mammographic findings of breast amyloidosis are mul-
tiple nodules with or without calcifications [2, 4–6].
O’Brien et al. reported that amyloidosis of the breast
demonstrates low signal intensity on T1-weighed
magnetic resonance imaging (MRI) and high signal
intensity on T2-weighted MRI [7]. Reports on ultra-
sonographic findings of breast amyloidosis are rare
[8].
Breast amyloidosis typically appears as diffuse
breast involvement in the systemic form of amyloid-
osis, however, this condition can also be localized to
the breast only. A study from the Mayo Clinic
reviewed 40 cases of amyloidosis of the breast, and
demonstrated that systemic amyloidosis accounted
for nearly 50 % of all cases [3]. Moreover, concur-
rent hematologic malignancies were found in associ-
ation with amyloidosis of the breast in 55 % of all
patients.
Amyloidosis is classified as (i) primary amyloidosis and
amyloidosis related to multiple myeloma (light chain
amyloidosis [AL]), (ii) secondary amyloidosis (amyloid A
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amyloidosis [AA]), or (iii) familial amyloidosis (amyloi-
dogenic transthyretin [ATTR]) on the basis of the chem-
ical composition of the tumors. The most common type
of amyloid is AL. The kappa light chain type is more fre-
quently found than the lambda light chain type. Second-
ary amyloidosis is characterized by the deposition of the
acute-phase protein serum amyloid A (SAA). Secondary
amyloidosis is caused by an underlying chronic inflam-
matory disease such as rheumatoid arthritis or a malig-
nant tumor. AA amyloid disappears after permanganic
acid treatment. Familial amyloid polyneuropathy is one
type of hereditary generalized amyloidosis. This disease
is caused by a mutation in the transthyretin (TTR) gene,
with the ATTR type being usually identified.
Breast biopsy is necessary to make a definite diagnosis
of amyloidosis of the breast, in order to avoid unneces-
sary surgical interventions. Localized primary amyloid-
osis of the breast has a good prognosis. However,
secondary amyloidosis is caused by a systemic disease
and has a poor prognosis [9]. The main treatment of pri-
mary amyloidosis of the breast is surgical removal [4].
Case presentation
A 77-year-old Japanese woman noticed a hard, non-
tender lump in the left lower inner part of her breast
and visited the outpatient clinic for breast surgery on
September 24 2014. She had no family history of amyl-
oidosis or breast cancer. She had hypertension, angina
pectoris, and arteriosclerosis. She also had an operation
history: abdominal total hysterectomy and bilateral
salpingo-oophorectomy for myoma uteri at the age of
52 years.
A hard lump was palpable on the left lower inner part
of her breast. The mammogram showed no mass or
pleomorphic calcifications in both breasts: however, a
focal asymmetric density was observed on the inner side
of the left breast in the craniocaudal view, which was
assessed as BI-RADS category 3 (Fig. 1). On breast ultra-
sonogoraphy, an irregular low echoic area was observed
at the site of the lump (Fig. 2). No blood flows were seen
entering the low echoic area. Elastography (elasticity
imaging technique) revealed that the low echoic area
was soft, a finding that is different from that of breast
cancer.
An ultrasound-guided core needle biopsy was done to
rule out breast cancer. Hematoxylin and eosin staining
revealed eosinophilic material in the extracellular area.
The specimen was positive for Congo red staining even
after permanganic acid treatment, and exhibited yellow-
green birefringence under polarizing microscopy.
Further examinations were carried out to rule out
plasma cell myeloma, other B cell tumors, or systemic
amyloidosis according to National Comprehensive Can-
cer Network Clinical Practice Guidelines in Oncology.
The patient had neither M-protein in serum immune
electrophoresis nor Bence-Jones protein in urine im-
mune electrophoresis examination. Bone marrow aspir-
ation was negative for plasma cell myeloma or other B
cell tumors. No lymphadenopathy was seen on com-
puted tomography. Electrocardiogram and cardiac ultra-
sonography showed no evidence of cardiomyopathy or
amyloidosis related changes. Stomach, rectum, bone
marrow, and random skin biopsies were performed and
none of biopsies showed evidence of amyloidosis. Taken
together, systemic amyloidosis and multiple myeloma
were ruled out, and localized breast amyloidosis was
highly suspected.
To make a definite diagnosis, lumpectomy was per-
formed on December 25, 2014. Macroscopic specimens
Fig. 1 Mammogram findings. The bilateral craniocaudal view of the
mammograms demonstrated focal asymmetry in the outer left
breast. No pleomorphic calcifications was seen
Tsuji et al. BMC Surgery  (2016) 16:62 Page 2 of 5
of the mammary gland showed abnormal white masses
as arrows indicate (Fig. 3). The final pathology demon-
strated homogenous eosinophilic depositions with sur-
rounding margins of breast parenchyma (Fig. 4). The
deposits were positive to Congo red and direct fast scar-
let (DFS) staining after permanganic acid treatment
(Fig. 4). Immunohistochemistry for AA amyloid was
negative. No malignancy such as breast carcinoma,
lymphoma, or plasma cell myeloma was seen.
For further immunohistochemical staining, specimens
were sent to the Department of Neurology of Kuma-
moto University. Amyloid typing with immunohisto-
chemistry was performed using antibodies directed
against the following antigens: polyclonal rabbit anti-
Fig. 2 Ultrasonographic findings. Breast ultrasonogram showed an irregular low echoic area in the inner lower quadrant. No blood flows were
present in the low echoic area, and elastography revealed that the area was soft unlike breast cancer
Fig. 3 Macroscopic view of the specimen. The macroscopic breast
specimens showed abnormal white masses as arrows indicate
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human prealbumin (TTR) (DAKO), monoclonal mouse
anti-human amyloid A (clone mc1) (DAKO), polyclonal
rabbit anti-human kappa light chains (DAKO), poly-
clonal rabbit anti-human lambda light chains (DAKO),
anti-human kappa light chain monoclonal antibody,
clone H16-E (Novus Biologicals), anti-IGLL5 immuno-
globulin lambda-like polypeptide 5, rabbit-Poly (Novus
Biologicals), rabbit monoclonal antibody [EP1368Y] to
apolipoprotein A-I (Abcam), and polyclonal rabbit anti-
human beta-2-microglobulin (DAKO). The resected
breast tissue was positive for Congo red, IgLCk (im-
munoglobulin light chain kappa [polyclonal]), and Kmab
(immunoglobulin light chain kappa [monoclonal]) (Fig. 5).
Under polarized light, the protein exhibited yellow-green
birefringence. The specimen was negative for serum amyl-
oid A (SAA), TTR, IgLCλ (immunoglobulin light chain
lambda [polyclonal]), and IGLL5 (immunoglobulin
lambda-like polypeptide 5) (Fig. 5). The amyloidosis was
shown to be the ALk type, which is more frequently en-
countered than the ALλ type [10]. The patient was free
from any lymphoid malignancies or immunological disor-
ders. Therefore, the final diagnosis was primary amyloid-
osis of the breast.
The patient is currently being followed-up at our insti-
tution, and has shown no evidence of disease recurrence
or breast cancer at 1 year after the surgery.
This report highlights imaging and histopathological
assessment of amyloidosis of the breast. Amyloidosis of
Fig. 4 Microscopic observations (hematoxylin and eosin [H&E], direct fast scarlet [DFS], Congo red, Congo red after permanganic acid treatment,
and amyloid L). H&E staining showed homogenous eosinophilic depositions with surrounding margins of breast parenchyma. No malignancy
such as breast carcinoma, lymphoma, or plasma cell myeloma was seen. The deposits were positive to Congo red and DFS staining after
permanganic acid treatment. Immunohistochemistry for AA amyloid was negative
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the breast is rare and should be distinguished from
breast cancer, and histological assessment is necessary.
Conclusions
Localized primary amyloidosis of the breast is a very rare
benign disease characterized by abnormal protein depos-
ition in the mammary glands. This case of primary
breast amyloidosis was experienced for the first time in
the recent 27 years at our institution. The current stand-
ard of care of primary breast amyloidosis is surgical re-
section, and systemic therapy is not necessary [4].
Localized primary amyloidosis of the breast has a good
prognosis; however, the patient should be followed after
surgery when recurrence or malignancy occurs.
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Fig. 5 Immunohistochemistry. The resected breast tissue was positive for Congo red (CR), IgLCk (immunoglobulin light chain kappa [polyclonal]),
and Kmab (immunoglobulin light chain kappa [monoclonal])(Fig. 5). Under polarized light, the protein exhibited yellow-green birefringence. The
specimen was negative for SAA (serum amyloid A), TTR (transthyretin), IgLCλ (immunoglobulin light chain lambda [polyclonal]), and IGLL5 (immuno-
globulin lambda-like polypeptide 5)
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